Minireview: A skeleton in serotonin's closet?

Endocrinology

Volumn 151, Issue 9, 2010, Pages 4103-4108

  Kawai, Masanobu ^a   Rosen, Clifford J ^a  

^a Maine Medical Center Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR;

ANIMAL; BIOLOGICAL MODEL; BONE REMODELING; DRUG EFFECTS; HUMAN; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; BONE REMODELING; HUMANS; MODELS, BIOLOGICAL; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 77956047688     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2010-0499     Document Type: Short Survey

References (46)

1. Garfield AS, Heisler LK 2009 Pharmacological targeting of the serotonergic system for the treatment of obesity. J Physiol 587:49-60
2. Gaspar P, Cases O, Maroteaux L 2003 The developmental role of serotonin: news from mouse molecular genetics. Nat Rev Neurosci 4:1002-1012
3. Berger M, Gray JA, Roth BL 2009 The expanded biology of serotonin. Annu Rev Med 60:355-366
4. Rosen CJ 2008 Bone remodeling, energy metabolism, and the molecular clock. Cell Metab 7:7-10
5. Rosen CJ, Klibanski A 2009 Bone, fat, and body composition: evolving concepts in the pathogenesis of osteoporosis. Am J Med 122:409-414
6. Friedman JM 2009 Leptin at 14 y of age: an ongoing story. Am J Clin Nutr 89:973S-979S
7. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen J, Vinson C, Rueger JM, Karsenty G 2000 Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100:197-207
8. Elefteriou F, Ahn JD, Takeda S, Starbuck M, Yang X, Liu X, Kondo H, Richards WG, Bannon TW, Noda M, Clement K, Vaisse C, Karsenty G 2005 Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 434:514-520
9. Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, Armstrong D, Ducy P, Karsenty G 2002 Leptin regulates bone formation via the sympathetic nervous system. Cell 111:305-317
10. Fuller RW, Wong DT 1990 Serotonin uptake and serotonin uptake inhibition. Ann NY Acad Sci 60:68-78; discussion 79-80
11. Furness JB, Costa M 1982 Neurons with 5-hydroxytryptamine-like immunoreactivity in the enteric nervous system: their projections in the guinea-pig small intestine. Neuroscience 7:341-349 (Pubitemid 12168723)
12. Walther DJ, Peter JU, Bashammakh S, Hörtnagl H, Voits M, Fink H, Bader M 2003 Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science 299:76
13. Jonnakuty C, Gragnoli C 2008 What do we know about serotonin? J Cell Physiol 217:301-306
14. Zhang X, Beaulieu JM, Sotnikova TD, Gainetdinov RR, Caron MG 2004 Tryptophan hydroxylase-2 controls brain serotonin synthesis. Science 305:217 (Pubitemid 38886729)
15. Westbroek I, van der Plas A, de Rooij KE, Klein-Nulend J, Nijweide PJ 2001 Expression of serotonin receptors in bone. J Biol Chem 276:28961-28968
16. Bliziotes M, Eshleman A, Burt-Pichat B, Zhang XW, Hashimoto J, Wiren K, Chenu C 2006 Serotonin transporter and receptor expression in osteocytic MLO-Y4 cells. Bone 39:1313-1321
17. Bliziotes MM, Eshleman AJ, Zhang XW, Wiren KM 2001 Neurotransmitter action in osteoblasts: expression of a functional system for serotonin receptor activation and reuptake. Bone 29:477-486
18. Battaglino R, Fu J, Späte U, Ersoy U, Joe M, Sedaghat L, Stashenko P 2004 Serotonin regulates osteoclast differentiation through its transporter. J Bone Miner Res 19:1420-1431
19. Yadav VK, Oury F, Suda N, Liu ZW, Gao XB, Confavreux C, Klemenhagen KC, Tanaka KF, Gingrich JA, Guo XE, Tecott LH, Mann JJ, Hen R, Horvath TL, Karsenty G 2009 A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell 138:976-989
20. Warden SJ, Robling AG, Sanders MS, Bliziotes MM, Turner CH 2005 Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth. Endocrinology 146:685-693
21. Yadav VK, Ryu JH, Suda N, Tanaka KF, Gingrich JA, Schütz G, Glorieux FH, Chiang CY, Zajac JD, Insogna KL, Mann JJ, Hen R, Ducy P, Karsenty G 2008 Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 135:825-837
22. Modder UI, Achenbach SJ, Amin S, Riggs BL, Melton LJ, Khosla S 2010 Relation of serum serotonin levels to bone density and structural parameters in women. J Bone Miner Res 25:414-422
23. Kuroki T, Nagao N, Nakahara T 2008 Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. Prog Brain Res 172:199-212
24. Gründer G, Hippius H, Carlsson A 2009 The 'atypicality' of antipsychotics: a concept re-examined and re-defined. Nat Rev Drug Discov 8:197-202
25. Halbreich U, Palter S 1996 Accelerated osteoporosis in psychiatric patients: possible pathophysiological processes. Schizophr Bull 22:447-454 (Pubitemid 26295347)
26. Howard L, Kirkwood G, Leese M 2007 Risk of hip fracture in patients with a history of schizophrenia. Br J Psychiatry 190:129-134
27. Meltzer HY, Matsubara S, Lee JC 1989 Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 251:238-246
28. Bostwick JR, Guthrie SK, Ellingrod VL 2009 Antipsychotic-induced hyperprolactinemia. Pharmacotherapy 29:64-73
29. Dick-de-Paula I, Welch G, Kawai M, Maloney A, Bornstein S, Sikich L, Rosen CJ Risperidone, a second generation antipsychotic alters fat distribution and has a deleterious effect on bone mass in young C57BL6 male mice. Program of the 92nd Annual Meeting of The Endocrine Society, San Diego, CA, 2010
30. Vestergaard P, Rejnmark L, Mosekilde L 2008 Selective serotonin reuptake inhibitors and other antidepressants and risk of fracture. Calcif Tissue Int 82:92-101
31. Diem SJ, Blackwell TL, Stone KL, Yaffe K, Haney EM, Bliziotes MM, Ensrud KE 2007 Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med 167:1240-1245
32. Liu B, Anderson G, Mittmann N, To T, Axcell T, Shear N 1998 Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people. Lancet 351:1303-1307
33. Lewis CE, Ewing SK, Taylor BC, Shikany JM, Fink HA, Ensrud KE, Barrett-Connor E, Cummings SR, Orwoll E 2007 Predictors of non-spine fracture in elderly men: the MrOS study. J Bone Miner Res 22:211-219
34. Bolton JM, Metge C, Lix L, Prior H, Sareen J, Leslie WD 2008 Fracture risk from psychotropic medications: a population-based analysis. J Clin Psychopharmacol 28:384-391
35. Richards JB, Papaioannou A, Adachi JD, Joseph L, Whitson HE, Prior JC, Goltzman D 2007 Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med 167:188-194 (Pubitemid 46148067)
36. Calarge CA, Zimmerman B, Xie D, Kuperman S, Schlechte JA 2010 A cross sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys. J Clin Psychiatry 71:338-347
37. Ziere G, Dieleman JP, van der Cammen TJ, Hofman A, Pols HA, Stricker BH 2008 Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures. J Clin Psychopharmacol 28:411-417
38. Warden SJ, Hassett SM, Bond JL, Rydberg J, Grogg JD, Hilles EL, Bogenschutz ED, Smith HD, Fuchs RK, Bliziotes MM, Turner CH 2010 Psychotropic drugs have contrasting skeletal effects that are independent of their effects on physical activity levels. Bone 46: 985-992
39. Battaglino R, Vokes M, Schulze-Späte U, Sharma A, Graves D, Kohler T, Müller R, Yoganathan S, Stashenko P 2007 Fluoxetine treatment increases trabecular bone formation in mice. J Cell Biochem 100:1387-1394
40. Maurer-Spurej E, Pittendreigh C, Solomons K 2004 The influence of selective serotonin reuptake inhibitors on human platelet serotonin. Thromb Haemost 91:119-128
41. Homberg JR, Schubert D, Gaspar P 2010 New perspectives on the neurodevelopmental effects of SSRIs. Trends Pharmacol Sci 31:60-65
42. Narboux-Nême N, Pavone LM, Avallone L, Zhuang X, Gaspar P 2008 Serotonin transporter transgenic (SERTcre) mouse line reveals developmental targets of serotonin specific reuptake inhibitors (SSRIs). Neuropharmacology 55:994-1005
43. Kawai M, Devlin MJ, Rosen CJ 2009 Fat targets for skeletal health. Nat Rev Rheumatol 5:365-372
44. Dhillon H, Zigman JM, Ye C, Lee CE, McGovern RA, Tang V, Kenny CD, Christiansen LM, White RD, Edelstein EA, Coppari R, Balthasar N, Cowley MA, Chua Jr S, Elmquist JK, Lowell BB 2006 Leptin directly activates SF1 neurons in the VMH, and this action by leptin is required for normal body-weight homeostasis. Neuron 49: 191-203
45. Kema IP, de Vries EG, Schellings AM, Postmus PE, Muskiet FA 1992 Improved diagnosis of carcinoid tumors by measurement of platelet serotonin. Clin Chem 38:534-540
46. Meijer WG, van der Veer E, Jager PL, van der Jagt EJ, Piers BA, Kema IP, de Vries EG, Willemse PH 2003 Bone metastases in carcinoid tumors: clinical features, imaging characteristics, and markers of bone metabolism. J Nucl Med 44:184-191